Sugi Predict

Sugi Predict / Compounds / SCHEMBL667807

SCHEMBL667807

SCHEMBL667807

Nc1ccc(NC(=O)c2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BCAT2 O15382 1/20 0.77
▸ MEN1 O00255 5/20 0.75
▸ KMT2A Q03164 5/20 0.75
▸ KDM4E B2RXH2 3/20 0.75
▸ NPC1 O15118 3/20 0.75
▸ RAB9A P51151 3/20 0.75
▸ PKM P14618 2/20 0.75
▸ MAPT P10636 2/20 0.75
▸ LMNA P02545 2/20 0.68
▸ POLB P06746 2/20 0.68
▸ APEX1 P27695 1/20 0.68
▸ TDP1 Q9NUW8 1/20 0.68
▸ KCNQ3 O43525 1/20 0.61
▸ KCNQ2 O43526 1/20 0.61
▸ KCNE1 P15382 1/20 0.61
▸ KCNQ1 P51787 1/20 0.61
▸ SNCA P37840 1/20 0.57
▸ PRMT1 Q99873 1/20 0.56
▸ PTGS1 P23219 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL684093 0.90 NPC1 (0.75) BCAT2MEN1KMT2AKDM4ENPC1
SCHEMBL14972636 0.89 MEN1 (0.66) BCAT2MEN1KMT2AKDM4ENPC1
SCHEMBL29771723 0.89 MEN1 (0.66) BCAT2MEN1KMT2AKDM4ENPC1
SCHEMBL14972649 0.89 MEN1 (0.66) BCAT2MEN1KMT2AKDM4ENPC1
SCHEMBL4254150 0.86 MEN1 (0.80) BCAT2MEN1KMT2AKDM4ENPC1
SCHEMBL2982452 0.85 MEN1 (0.77) BCAT2MEN1KMT2AKDM4ENPC1
Hydrochloric Acid SCHEMBL3717981 0.84 SIRT2 (0.60) BCAT2MEN1KMT2AKDM4ENPC1
SCHEMBL4254970 0.83 RAB9A (0.75) BCAT2MEN1KMT2AKDM4ENPC1
SCHEMBL3089807 0.83 MEN1 (0.75) BCAT2MEN1KMT2AKDM4ENPC1
SCHEMBL3645013 0.83 MEN1 (0.74) BCAT2MEN1KMT2AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-11-03 — — US claimed
JP-2011526912-A — — 2011-10-20 — — JP claimed
EP-2291376-A2 NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS Merck Patent GmbH (DE) 2011-03-09 — — EP claimed
WO-2010002779-A2 NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS MERCK SERONO S.A. (CH) 2010-01-07 — — WO claimed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 — — US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 — — US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 — — US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 — — EP disclosed
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-11-03 — — US disclosed
EP-2291376-A2 NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS Merck Patent GmbH (DE) 2011-03-09 — — EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 — — US disclosed
EP-2254889-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF Merck Patent GmbH (DE) 2010-12-01 — — EP disclosed
WO-2010002779-A2 NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS MERCK SERONO S.A. (CH) 2010-01-07 — — WO disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS AURKA, AURKC, AURKB BCAT2 2184/4885MEN1 1490/4885KMT2A 1060/4885
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK BCAT2 1798/4885MEN1 544/4885KMT2A 921/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK BCAT2 1993/4885MEN1 1218/4885KMT2A 1345/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK BCAT2 1798/4885MEN1 544/4885KMT2A 921/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK BCAT2 1315/4885MEN1 636/4885KMT2A 929/4885
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 BCAT2 1002/4885MEN1 3455/4885KMT2A 2055/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK BCAT2 1315/4885MEN1 636/4885KMT2A 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.